Enliven Therapeutics, Inc.
ELVN
$27.25
-$0.54-1.94%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -27.99% | 12.99% | -26.99% | -25.53% | -19.67% |
| Total Depreciation and Amortization | -42.50% | -22.50% | 3.85% | -6.33% | 2.56% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 96.10% | 18.13% | 106.33% | 73.89% | 376.00% |
| Change in Net Operating Assets | 339.02% | -103.15% | 107.14% | 46.15% | -109.33% |
| Cash from Operations | 7.93% | -8.91% | 16.53% | -3.28% | -37.82% |
| Capital Expenditure | -- | 104.55% | -6,850.00% | 0.00% | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 1,573.45% | -127.34% | -444.96% | 108.10% | -98.12% |
| Cash from Investing | 1,602.75% | -127.37% | -445.34% | 107.98% | -98.12% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -98.20% | -- | 11,991.81% | -99.74% | 44,313.33% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -98.44% | -132.95% | 11,991.81% | -99.74% | 44,313.33% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -112.07% | -572.13% | 133.91% | -145.83% | -10.64% |